Metagenomi (NASDAQ:MGX) Receives “Buy” Rating from HC Wainwright

by · The Cerbat Gem

HC Wainwright restated their buy rating on shares of Metagenomi (NASDAQ:MGX – Free Report) in a research note published on Tuesday, Benzinga reports. HC Wainwright currently has a $7.00 price objective on the stock.

A number of other research analysts have also commented on MGX. Chardan Capital restated a “buy” rating and issued a $15.00 target price on shares of Metagenomi in a research note on Thursday, September 5th. BMO Capital Markets lowered their price target on shares of Metagenomi from $22.00 to $17.00 and set an “outperform” rating on the stock in a report on Thursday, August 15th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $15.50.

Read Our Latest Analysis on Metagenomi

Metagenomi Trading Down 1.5 %

NASDAQ:MGX opened at $1.96 on Tuesday. Metagenomi has a one year low of $1.85 and a one year high of $12.74. The company has a fifty day moving average price of $2.57 and a 200 day moving average price of $4.79.

Metagenomi (NASDAQ:MGX – Get Free Report) last announced its quarterly earnings data on Wednesday, August 14th. The company reported ($0.29) EPS for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.30. The company had revenue of $20.01 million for the quarter, compared to analyst estimates of $14.80 million. On average, equities analysts expect that Metagenomi will post -3.04 EPS for the current fiscal year.

Institutional Investors Weigh In On Metagenomi

Large investors have recently made changes to their positions in the company. Resolute Advisors LLC acquired a new position in Metagenomi in the first quarter valued at about $106,000. Vanguard Group Inc. acquired a new position in shares of Metagenomi in the 1st quarter worth approximately $1,894,000. Altitude Crest Partners Inc. bought a new stake in Metagenomi during the 1st quarter worth approximately $1,407,000. Hhlr Advisors LTD. acquired a new stake in Metagenomi during the 1st quarter valued at $8,205,000. Finally, Artal Group S.A. bought a new position in Metagenomi in the 1st quarter valued at $3,165,000.

Metagenomi Company Profile

(Get Free Report)

Metagenomi, Inc, a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.

Featured Stories